VolitionRx is a biotech
small-cap dedicated to the development of blood-based diagnostic tests for
different types of cancer, with an initial focus on colorectal cancer, the
second deadliest cancer in the United States. After the age of 50, healthcare
experts recommend a colonoscopy every five-10 years. Between these
colonoscopies, people can use non-invasive tests that can sometimes determine
the presence of cancer or even precancers. And here’s where VolitionRx steps
in.
Currently, there are three
main types of routing colorectal screening tests: Fecal occult blood tests
(FOBT), Fecal immunochemical tests (FIT), and stool DNA tests (sDNA). Each type
of test has its own drawback, and VolitionRx aims to fill the gap with
accurate, non-invasive cancer blood tests that are easy and simple to use.
FOBTs are used the most
frequently used test, most likely because of they are available for less than
$25, and while a bit uncomfortable at the thought, are not physically invasive.
However, these tests have a high false positive rate and low precancerous
detection rate. Patients can also get a false positive with an FOBT if they
have consumed vitamins, red meat, or fruits and vegetables prior to their bowel
movement.
The FIT also detects blood
in the stool, though it achieves a higher detection rate (37 percent) than
FOBT. FIT is an immunochromatography-based test that detects hidden blood in
the stool, which can be a sign of precancerous polyps or colon cancer. Because
of the way it works, it does not give a false positive when patients eat
certain fruits or vegetables. The downsides to this test are the approximately
$100 cost and the fact that they may miss tumors that bleed in small amounts or
not at all.
According to the Colon
Cancer Alliance, a new generation of stool DNA tests is on the horizon. These
tests have the potential to detect tumors at an early stage, including those
not picked up by a colonoscopy, by focusing on a different process in the
cancer cells and measuring mutations in DNA. While these are more accurate than
blood tests, no single mutation predicts a patient’s risk and researchers have
not seen a decisive improvement. In addition, these tests are very pricey,
averaging $300 a piece.
Early detection provides the
greatest chance for curing the disease and for survival, though 20-40 percent
of patients are diagnosed with colorectal cancer in the later stages, when
surgical removal is not a curative option. The majority of screens that catch
polyps will find them while they are adenomas vs. precancerous polyps, the
stage at which cancer is best prevented.
VolitionRx is developing two
types of non-invasive cancer diagnostic tests based on its patented
Nucleosomics® technology, supporting the company’s overarching goal to bring to
market its cancer blood tests and revolutionize cancer diagnosis.
While VolitionRx’s current
focus is on the detection of colorectal cancer, future plans call for expansion
into detection of various other cancers as well. Following ongoing clinical
trials and regulatory approval, the company plans to offer its tests for
individualized cancers under the NuQ® brand.
VolitionRx has developed a
range of about 20 individual assays, and plans to continue developing
additional assays; an optimal panel of assays (typically 4-5) will then be
selected. Each panel of tests requires a very small amount of blood, can be
turned around in a day, and is very cost effective.
In December, 2013,
VolitionRx announced findings that when combining two of its proprietary NuQ®
assays into one test, they can achieve 85 percent detection rates at 85 percent
specificity for colorectal cancer. The data also shows that Volition’s
two-assay test can detect more than 50 percent of precancerous polyps.
The company’s R&D
efforts are in Belgium, as the company markets its products in Europe where
there is an easier path to regulatory approval. VolitoinRx plans to expand its
marketing and commercialization to the United States, and then to the rest of
the world.
For more information visit
www.volitionrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
